- Conditions
- Non-small Cell Lung Cancer, Melanoma
- Interventions
- IMM60, Pembrolizumab
- Drug
- Lead sponsor
- iOx Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 793–816
of 7,238
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 347
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
- Conditions
- Prostate Cancer, Neoplasm Metastasis
- Interventions
- MDX-010
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • New Haven, Connecticut + 9 more
- Conditions
- Antineutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- Avacopan, Placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2036
- U.S. locations
- 62
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more
- Conditions
- Urinary Incontinence
- Interventions
- Retzius sparing radical prostatectomy, Vattikuti Urology Institute radical prostatectomy, da Vinci Surgical System
- Procedure · Device
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 40 Years to 75 Years · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • West Bloomfield, Michigan
- Conditions
- Cancer
- Interventions
- MEDI-573
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, BMS-986205, BMS-813160
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
- Conditions
- Pulmonary Embolism
- Interventions
- Rivaroxaban, Standard-of-care
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 50
- States / cities
- Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2011
- U.S. locations
- 91
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 652
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- foretinib (formerly GSK1363089 or XL880)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 12
- States / cities
- Greenbrae, California • San Francisco, California • Stanford, California + 9 more
- Conditions
- Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Interventions
- Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, Sunitinib Malate, Trebananib
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 12
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 9 more
- Conditions
- Spasticity
- Interventions
- SPARC0921, Placebo0921
- Drug
- Lead sponsor
- Sun Pharma Advanced Research Company Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 56
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 50 more
- Conditions
- Hepatitis
- Interventions
- Larsucosterol, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
- Conditions
- HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
- Other · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
- Conditions
- Primary Prevention of Sudden Cardiac Arrest, Secondary Prevention of Sudden Cardiac Arrest
- Interventions
- S-ICD System
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,766 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 87
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 72 more
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
- Interventions
- Doxorubicin Hydrochloride, Irinotecan Hydrochloride, Conventional Surgery, Cyclophosphamide, Etoposide, Carboplatin, Dactinomycin, Vincristine Sulfate, Radiation Therapy, Laboratory Biomarker Analysis
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 29 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 161
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 127 more
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 531
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
- Conditions
- Anemia
- Interventions
- ferumoxytol or oral iron
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 19
- States / cities
- Encino, California • Riverside, California • Tarzana, California + 15 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- R-(-)-gossypol acetic acid, temozolomide, gene expression analysis, mutation analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, adjuvant therapy, radiation therapy
- Drug · Genetic · Other + 2 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 vaccine, Control
- Biological · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 9 Years to 49 Years · Female only
- Enrollment
- 3,855 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 27
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- GT103
- Drug
- Lead sponsor
- Edward Patz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Celebration, Florida • Detroit, Michigan • Durham, North Carolina